中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
34期
30-31,33
,共3页
伊立替康%氟尿嘧啶%晚期胃癌%二线治疗
伊立替康%氟尿嘧啶%晚期胃癌%二線治療
이립체강%불뇨밀정%만기위암%이선치료
Irinotecan%5-fluorouracil%Advanced gastric cancer%Second line therapy
目的：观察改良FOLFIRI方案（mFOLFIRI）在晚期胃癌二线治疗中的疗效和不良反应。方法回顾性分析我院41例晚期胃癌患者，接受mFOLFIRI方案治疗：伊立替康180 mg/m2，静脉滴注90 min，第1天；亚叶酸钙（CF）200 mg/m2，静脉滴注2 h，第1天；5-氟尿嘧啶（5-Fu）400 mg/m2，静脉推注，第1天；5-Fu 2.4g/m2，静脉滴注46 h（泵）；14d为一个周期，4周期评价疗效，每周期评价不良反应。结果41患者均可评价疗效，完全缓解（CR）0例（0%）、部分缓解（PR）7例（17.1%）、稳定（SD）13例（31.7%），进展（PD）21例（51.2%），疾病控制率（DCR）（CR+PR+SD）48.8%；中位疾病进展时间（mTTP）为3.4个月，中位生存期（mOS）为9.1个月。主要不良反应为骨髓抑制及迟发性腹泻，另有恶心呕吐及轻度肝肾功能损伤，经对症治疗后均可缓解。结论 mFOLFIRI方案二线治疗晚期胃癌疗效肯定，且不良反应可耐受。
目的：觀察改良FOLFIRI方案（mFOLFIRI）在晚期胃癌二線治療中的療效和不良反應。方法迴顧性分析我院41例晚期胃癌患者，接受mFOLFIRI方案治療：伊立替康180 mg/m2，靜脈滴註90 min，第1天；亞葉痠鈣（CF）200 mg/m2，靜脈滴註2 h，第1天；5-氟尿嘧啶（5-Fu）400 mg/m2，靜脈推註，第1天；5-Fu 2.4g/m2，靜脈滴註46 h（泵）；14d為一箇週期，4週期評價療效，每週期評價不良反應。結果41患者均可評價療效，完全緩解（CR）0例（0%）、部分緩解（PR）7例（17.1%）、穩定（SD）13例（31.7%），進展（PD）21例（51.2%），疾病控製率（DCR）（CR+PR+SD）48.8%；中位疾病進展時間（mTTP）為3.4箇月，中位生存期（mOS）為9.1箇月。主要不良反應為骨髓抑製及遲髮性腹瀉，另有噁心嘔吐及輕度肝腎功能損傷，經對癥治療後均可緩解。結論 mFOLFIRI方案二線治療晚期胃癌療效肯定，且不良反應可耐受。
목적：관찰개량FOLFIRI방안（mFOLFIRI）재만기위암이선치료중적료효화불량반응。방법회고성분석아원41례만기위암환자，접수mFOLFIRI방안치료：이립체강180 mg/m2，정맥적주90 min，제1천；아협산개（CF）200 mg/m2，정맥적주2 h，제1천；5-불뇨밀정（5-Fu）400 mg/m2，정맥추주，제1천；5-Fu 2.4g/m2，정맥적주46 h（빙）；14d위일개주기，4주기평개료효，매주기평개불량반응。결과41환자균가평개료효，완전완해（CR）0례（0%）、부분완해（PR）7례（17.1%）、은정（SD）13례（31.7%），진전（PD）21례（51.2%），질병공제솔（DCR）（CR+PR+SD）48.8%；중위질병진전시간（mTTP）위3.4개월，중위생존기（mOS）위9.1개월。주요불량반응위골수억제급지발성복사，령유악심구토급경도간신공능손상，경대증치료후균가완해。결론 mFOLFIRI방안이선치료만기위암료효긍정，차불량반응가내수。
Objective To observe efficiency and toxicity of modified FOLFIRI (mFOLFIRI) as the second line chemotherapy regimen in treating with advanced gastric cancer (AGC). Methods Forty-one patients with AGC received mFOLFIRI regimen were enrolled retrospectively. The regimen included irinotecan 180 mg/m2 intravenous in 90 minutes on day 1, calcium folinate 200mg/m2 intravenous on day 1, 5-fluorouracil 400mg on bolus on day 1 and 2.4g/m2 continuous intravenous infusion in the following 46 hours. 2 weeks repeated as one cycle. Clinical responses were assessed every 4 cycles of chemotherapy and toxicity every cycle. Results There were 0 case(0%) assessed with complete response (CR), 7 cases (17.1%) with partial response (PR), 13 cases (31.7%) with stable disease (SD), 21 cases(51.2%) with progress disease(PD). The total clinic control response rate(DCR) (CR+PR+SD) was 48.8%. The median time to progress and overall survival of these patients was 3.4 and 9.1 months, respectively. Drug related toxicities were bone narrow depression and delayed diarrhoea reaction and so on. Conclusion mFOLFIRI regimen possesses good efficiency and acceptable toxicity in treating with AGC patients and it is worth of further study.
